| 2023-08-23 |
复牌提示：
2023-08-22 19:50:03 停牌，复牌日期 2023-08-24 00:00:01
|
| 2023-08-23 |
详情>>
内部人交易：
Wertheimer Samuel P等共交易12笔
|
| 2023-08-10 |
详情>>
股本变动：
变动后总股本2486.19万股
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.5美元,归母净利润-1210万美元,同比去年增长-192.94%
|
| 2023-06-30 |
股东大会：
将于2023-08-22召开股东大会
会议内容 ▼▲
- 1.To adopt the Agreement and Plan of Merger, dated May 23, 2023, among Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology”), Ascent Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of Pyxis Oncology (“Merger Sub”), and Apexigen, Inc., a Delaware corporation (“Apexigen”), as may be amended from time to time (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into Apexigen, with Apexigen continuing as the Surviving Corporation (as defined herein) and a wholly owned subsidiary of Pyxis Oncology (the “Merger”). A copy of the Merger Agreement is attached as Annex A to the proxy statement/prospectus accompanying this notice. This proposal is referred to as the “Apexigen merger proposal.”
2.To approve the adjournment from time to time of the Apexigen special meeting, if necessary, to solicit additional proxies if there are insufficient shares of Apexigen common stock present or represented by proxy at the Apexigen special meeting to constitute a quorum at the Apexigen special meeting or any adjournment or postponement thereof. This proposal is referred to as the “Apexigen adjournment proposal.”
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.25美元,归母净利润-605.3万美元,同比去年增长-146.29%
|
| 2023-02-22 |
详情>>
业绩披露：
2022年年报每股收益-1.62美元,归母净利润-3206.9万美元,同比去年增长-6524.98%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.36美元,归母净利润-2563.8万美元,同比去年增长-6714.94%
|
| 2022-08-18 |
详情>>
业绩披露：
2022年中报每股收益-0.57美元,归母净利润-413.05万美元,同比去年增长-814.68%
|
| 2022-05-23 |
详情>>
业绩披露：
2022年一季报每股收益-0.33美元,归母净利润-245.77万美元,同比去年增长-1345.69%
|
| 2022-04-07 |
详情>>
业绩披露：
2021年年报每股收益-0.07美元,归母净利润-48.41万美元,同比去年增长-26322.6%
|
| 2022-03-28 |
股东大会：
将于2022-04-26召开股东大会
会议内容 ▼▲
- 1.To amend (the “Extension Amendment”) the Company’s Amended and Restated Certificate of Incorporation (our “charter”) to extend the date by which the Company must consummate a Business Combination (as defined below) (the “Extension”) from May 2, 2022 (the date which is 15 months from the closing date of the Company’s initial public offering of our units (the “IPO”)) on a monthly basis up to November 2, 2022 (the date which is 21 months from the closing date of the IPO) (the “Extended Date”).
|
| 2021-12-09 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.06美元,归母净利润-37.62万美元,同比去年增长-20435.1%
|
| 2021-08-16 |
详情>>
业绩披露：
2021年中报每股收益-0.07美元,归母净利润-45.16万美元,同比去年增长-61844.58%
|